MRI影像组学分析改进早期宫颈癌多模式治疗候选者的无创治疗前识别
本研究纳入2017年1月至2021年2月235例接受根治性子宫切除术的IB1-IIA1期宫颈癌患者,基于术前矢状位T2加权图像提取影像组学特征,构建结合影像组学标签与临床病理参数的临床-影像组学模型,用于识别多模式治疗候选者。测试集中该模型AUC为0.885(95%CI:0.781-0.989),敏感度78.9%,特异度81.8%,优于临床模型和临床-常规影像模型;决策曲线分析显示阈值概率>20%时临床-影像组学模型或列线图可能优于全治疗或全不治疗策略。
要点
- 临床-影像组学模型在测试集识别多模式治疗候选者的AUC为0.885(95%CI:0.781-0.989)。
- 该模型敏感度78.9%、特异度81.8%,优于临床模型和临床-常规影像模型。
- 阈值概率>20%时,临床-影像组学模型或列线图可能优于全治疗或全不治疗策略。
核心结论
- 临床-影像组学模型和列线图可能识别早期宫颈癌患者中的多模式治疗候选者。
研究设计与样本
- 研究论文;2017年1月至2021年2月纳入235例接受根治性子宫切除术的IB1-IIA1期宫颈癌患者,按手术时间分为训练集194例(训练:验证=8:2)和测试集41例;从术前矢状位T2加权图像提取影像组学特征;采用显著性检验、Pearson相关分析和最小绝对收缩与选择算子筛选与多模式治疗实施相关的影像组学特征;构建结合影像组学标签、年龄、2018年国际妇产科联盟(FIGO)分期、绝经状态和术前活检组织学类型的临床-影像组学模型,并构建临床模型和临床-常规影像模型。
诊断标准与关键数值
- 测试集中临床-影像组学模型AUC为0.885(95%CI:0.781-0.989),敏感度78.9%,特异度81.8%。
- 测试集中临床模型AUC为0.751(95%CI:0.603-0.900),敏感度63.2%,特异度63.6%。
- 测试集中临床-常规影像模型AUC为0.801(95%CI:0.661-0.942),敏感度73.7%,特异度68.2%。
- 决策曲线分析显示阈值概率>20%时,临床-影像组学模型或列线图可能优于全治疗或全不治疗策略。
临床应用与阅片要点
- 作者认为临床-影像组学模型和列线图可能识别早期宫颈癌患者中的多模式治疗候选者。
- 术前识别早期宫颈癌多模式治疗候选者有助于选择最佳初始治疗并降低严重并发症风险和治疗费用。
- 列线图便于个体化术前预测且表现良好。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To develop and validate a clinical-radiomics model that incorporates radiomics signatures and pretreatment clinicopathological parameters to identify multimodality therapy candidates among patients with early-stage cervical cancer.
METHODS: Between January 2017 and February 2021, 235 patients with IB1-IIA1 cervical cancer who underwent radical hysterectomy were enrolled and divided into training (n = 194, training:validation = 8:2) and testing (n = 41) sets according to surgical time. The radiomics features of each patient were extracted from preoperative sagittal T2-weighted images. Significance testing, Pearson correlation analysis, and Least Absolute Shrinkage and Selection Operator were used to select radiomic features associated with multimodality therapy administration. A clinical-radiomics model incorporating radiomics signature, age, 2018 Federation International of Gynecology and Obstetrics (FIGO) stage, menopausal status, and preoperative biopsy histological type was developed to identify multimodality therapy candidates. A clinical model and a clinical-conventional radiological model were also constructed. A nomogram and decision curve analysis were developed to facilitate clinical application.
RESULTS: The clinical-radiomics model showed good predictive performance, with an area under the curve, sensitivity, and specificity in the testing set of 0.885 (95% confidence interval: 0.781-0.989), 78.9%, and 81.8%, respectively. The AUC, sensitivity, and specificity of the clinical model and clinical-conventional radiological model were 0.751 (0.603-0.900), 63.2%, and 63.6%, 0.801 (0.661-0.942), 73.7%, and 68.2%, respectively. A decision curve analysis demonstrated that when the threshold probability was > 20%, the clinical-radiomics model or nomogram may be more advantageous than the treat all or treat-none strategy.
CONCLUSIONS: The clinical-radiomics model and nomogram can potentially identify multimodality therapy candidates in patients with early-stage cervical cancer.
KEY POINTS: • Pretreatment identification of multimodality therapy candidates among patients with early-stage cervical cancer helped to select the optimal primary treatment and reduce severe complication risk and costs. • The clinical-radiomics model achieved a better prediction performance compared with the clinical model and the clinical-conventional radiological model. • An easy-to-use nomogram exhibited good performance for individual preoperative prediction.
引用
- Li, Ren, Yang, et al. MRI-derived radiomics analysis improves the noninvasive pretreatment identification of multimodality therapy candidates with early-stage cervical cancer. Eur Radiol. 2022. PMID: 35018480. doi:10.1007/s00330-021-08463-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。